Merck, known as MSD outside of the United States and Canada, and Orion Corporation (“Orion”) announced that notice has been provided of the mutual exercise of an option to convert the companies’ ongoing co-development and co-commercialization agreement for opevesostat (MK-5684/ODM-208), an investigational CYP11A1 inhibitor, and other candidates targeting CYP11A1 into an exclusive global license for Merck. Read more.
Pages
- Careers
- Certification of products subject to the requirements of the Consumer Product Safety Improvement Act of 2008 (CPSIA)
- Contact us
- Copyright
- Forward-looking statement
- ical
- Merck | Home
- Products list
- Responsible Vulnerability Disclosure Program of Merck & Co., Inc., Rahway, NJ, USA
- Sitemap
- Stories
- Terms of use
- What we do
- Who we are
- History
- Sustainability
- Access to health
- Environmental sustainability
- Impact Venture Fund
- Merck Medical Outreach Program
- Philanthropy
- Advancing equity in cancer care
- Advancing patient-centered cancer care
- Advancing patient-centered cancer care in resource-limited communities
- Enhancing diabetes care through community outreach and support
- Expanding access to cancer care in Asia
- Global emergency response
- Improving access to high-quality diabetes care
- Improving access to HIV care in sub-Saharan Africa
- Improving health care access
- Merck Foundation
- Merck Richard T. Clark Fellowship for Global Health
- Patient assistance and product donation programs
- Promoting equity in HIV/AIDS care
- Strengthening health systems’ resilience through immunization
- Strengthening our communities
- Sustainability resources
- Transparency disclosures
- Leadership
- Culture & values
- Diversity & inclusion
- Policies & positions
- Business development & licensing
- Suppliers
- Research
- Areas of focus
- Business development and licensing (BD&L)
- CHLOR-TRIMETON
- Immunology
- Meet our scientists
- Neuroscience
- Postdoctoral research fellows program
- Publications
- Scientific capabilities
- Vaccines
- COVID-19
- Infectious diseases
- Oncology
- Cardio-metabolic diseases
- Pipeline
- Discovery & development
- Clinical trials
- Diversity in clinical trials
- R&D locations
- Patients
- Investor relations
- Media
Archives
Categories
- No categories